DOCS vs RARE · P/E 21, rev $570.4M vs rev $560.2M
Doximity Inc (DOCS) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Doximity Inc (DOCS) is a health information services company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported DOCS revenue for 2025-03-31 was $570.4M. Net income was $223.2M. Revenue was up 20.0% from 2024-03-31 to 2025-03-31. DOCS currently screens at market cap $3.77B and trailing P/E 21.0.
Latest reported RARE revenue for 2024-12-31 was $560.2M. Net income was -$569.2M. Revenue was up 29.0% from 2023-12-31 to 2024-12-31. RARE currently screens at market cap $2.79B.
DOCS currently screens at market cap $3.77B and trailing P/E 21.0. RARE currently screens at market cap $2.79B.
Not investment advice. Open the DOCS and RARE stock pages for the full models.
Not investment advice.